$ONC

Wu Xiaobin sold $362K of ONC

Wu Xiaobin (President and COO) sold 1,357 shares of BeOne Medicines Ltd. (ONC) at $266.76 ($0.36M total) on 2026-06-16.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 18, 2026, 9:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

A president/COO open-market sale at a specific price is disclosed, but the filing provides no new company performance, guidance, or regulatory/clinical catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but this disclosure alone is unlikely to drive a fundamental repricing.

03

What to watch

Insider sales can be scheduled, tax-related, or tied to personal liquidity; without additional filings (other insiders, options exercises, or follow-on purchases), the signal is weak.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

SEC Form 4 shows ONC COO Wu Xiaobin sold 1,357 shares on 2026-06-16 at $266.7626, leaving 0 shares.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a small, non-accelerated sale with no stated reason, no buyback/financing, and no operational or regulatory catalyst.

Market effects

Minimal—single insider transaction without broader sector/regulatory signal.

None indicated.

None indicated.

Counterpoint

The officer has 0 shares after sale, but absence of a 10b5-1 plan and the small share count may indicate diversification/liquidity rather than a view on fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Company whose insider transaction is disclosed via SEC Form 4.

  • Wu Xiaobin

    President and COO who sold 1,357 shares on 2026-06-16.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.